Effect of Lactoferrin in Pneumonia Treatment

NCT05431023 | Unknown

• 1 other identifier: Pneumonia
• Study Type: interventional
• Target: 72
• Locations: 0 countries
• Sites: N/A

Brief Summary

Pneumonia is defind as the inflammation of lung tissue caused by an infectious agent that results in acute respiratory signs and symptoms. Community acquired pneumonia (CAP) is a major cause of morbidity and increased health care costs. In developing nations, pneumonia remains a significant cause of mortality in children. Pneumonia occurs in 30 to 45 of every 1,000 children under 5 years of age; it is less common in 5- to 9-year olds (16 to 22/1,000) and in older children (7 to 16/1,000). Streptococcus pneumoniae is the primary bacterial cause of pneumonia in infants and children. Viral etiologies become less prevalent and mycoplasmal and chlamydial infections become more prevalent with increasing age

Conditions

Pneumonia

Outcome Measures

Primary Outcomes (1)

• Survival rate.

  Comparing the influence of the intervention on the Survival rate.

  Up to 8 weeks

Secondary Outcomes (1)

• Mean change in the disease severity (clinical assessment)

  Up to 4 weeks

Study Arms (2)

Patients with pneumonia who receive only treatment for pneumonia

EXPERIMENTAL

They receive only treatment for pneumonia

Drug: Pneumonia treatment

pneumonia patients receive treatment for pneumonia and lactoferrin

EXPERIMENTAL

They receive treatment for pneumonia and lactoferrin

Drug: Lactoferrin; Drug: Pneumonia treatment

Interventions

Lactoferrin DRUG

Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection

pneumonia patients receive treatment for pneumonia and lactoferrin

Pneumonia treatment DRUG

Antibiotics for pneumonia

Patients with pneumonia who receive only treatment for pneumonia; pneumonia patients receive treatment for pneumonia and lactoferrin

Eligibility Criteria

• Age: 1 Month - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Pneumonia patients
• from the age of one month to the age of 18 years .

You may not qualify if:

• Neonates and any children with :
• immune deficiency
• congenital heart disease
• neuromascular disorder
• genetic syndromes

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Pneumonia

Interventions

Lactoferrin

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Serine Endopeptidases; Endopeptidases; Peptide Hydrolases; Hydrolases; Enzymes; Enzymes and Coenzymes; Serine Proteases; Glycoproteins; Glycoconjugates; Carbohydrates; Transferrins; Iron-Binding Proteins; Carrier Proteins; Proteins; Amino Acids, Peptides, and Proteins; Lactoglobulins; Whey Proteins; Milk Proteins; Animal Proteins, Dietary; Dietary Proteins; Globulins; Metalloproteins

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: March 12, 2022
• First Posted: June 24, 2022
• Study Start: August 1, 2022
• Primary Completion: August 1, 2023
• Study Completion: August 1, 2024
• Last Updated: June 24, 2022

Record last verified: 2022-06